🇺🇸

US SEC Filing Intelligence

· daily

US Material Events SEC 8-K Filings — March 18, 2026

Across 50 SEC 8-K filings from March 18, 2026, a dominant theme is extensive leadership churn with 25+ instances of C-suite appointments, resignations, and restructurings (e.g., CEOs, CFOs, COOs), signaling both proactive team-building (positive in 12 cases) and potential instability (neutral/mixed in 13). Financing activities proliferate, including $300M term loans (FTI), $2.25B term loan (Phillips 66), $40M loan facility (Hyperfine), and share repurchases ($125M ASR ExlService, $200M Accelerant), indicating strong liquidity access amid neutral-to-positive sentiment in 70% of cases. M&A/divestitures highlight strategic shifts: TriMas $1.45B aerospace sale, Independent Bank $70.2M acquisition, Energy Fuels ASM deal amendment, and RocketFuel asset sales. Period-over-period data shows outliers like Accelerant FY2025 premium +35% YoY to $4.19B and EBITDA +149% to $282M, Ovid FY2025 revenue +1122% YoY to $7.3M with op ex -20% YoY, but GAAP losses widened sharply; no broad margin compression but mixed net income trends. Capital allocation leans shareholder-friendly with buybacks and no dividend cuts reported. Portfolio implications favor monitoring industrials/energy for deal catalysts and biotechs for trial advancements, with overall positive sentiment (avg materiality 7.4/10) suggesting sector rotation opportunities into stable leadership transitions.

50 high priority 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — March 18, 2026

Across these 10 filings from the S&P 500 Technology stream (broadly including software, blockchain, semis, and adjacent), Micron Technology dominates with record Q2 FY2026 revenue of $23.86B (+75% QoQ, +196% YoY) and raised Q3 guidance to $33.5B ±$0.75B at 81% margins, signaling robust semiconductor demand. Contrasting sharply, dMY Squared reported widened net losses to $17.8M YoY amid surging G&A (+310%) and ballooning liabilities (+268% YoY), highlighting SPAC unwind risks. M&A and restructuring themes emerge with RocketFuel's non-binding asset sale term sheet retaining cash reserves, BlockchAIn's completed business combo unlocking AI/HPC data center revenue ($22.9M in 2024), and Creative Media's massive 261M+ share dilution for preferred redemptions. Capital allocation leans positive with Micron's 30% dividend hike to $0.15/share (record date March 30, 2026), while equity grants to ACNB execs and board elections/stability at Pineapple and ImmuCell add low-materiality positives. Period-over-period trends show 1/10 with explosive growth (Micron), 1/10 with sharp deterioration (dMY), and neutral restructuring in 3/10; no broad insider selling patterns, but interested-party transactions flagged. Sector implications point to AI/semiconductor strength amid blockchain/AI infra deals, but dilution and loss-making entities pressure smaller tech names.

7 high priority 3 medium 10 total filings
· daily

Nasdaq 100 Stocks SEC Filings — March 18, 2026

Across 11 NASDAQ-100 related filings, standout performance from Micron Technology with record Q2 FY2026 revenue up 75% QoQ ($13.64B to $23.86B) and 196% YoY ($8.05B), driving 74.4% GAAP gross margins (up from 36.8% YoY) and a 30% dividend hike to $0.15/share, signaling robust semiconductor demand amid AI boom. Biotech and metals sectors show clinical and operational progress (MetaVia Phase 1 approval, ImmuCell board addition, Welsbach video), while Faraday Future's $500k employee share repurchase aligns management with shareholders. Dilution risks emerge in Creative Media & Community Trust's issuance of over 261M common shares for preferred redemptions, potentially pressuring stock price. Neutral shelf registrations (Critical Metals F-3) and governance updates (Pineapple, Community Trust) indicate routine capital access and stability. Portfolio-level trends reveal margin expansion outliers in semis (Micron +3,760 bps YoY gross margin) contrasting dilution in REITs; forward catalysts cluster in Q2-Q4 2026 for biotech data and dividends. Overall, bullish tech/semiconductor momentum outweighs dilution and neutral fundraising themes, with actionable buys in high-growth leaders.

3 high priority 8 medium 11 total filings
· daily

Dow Jones 30 Stocks SEC Filings — March 18, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (March 18, 2026 period), overarching themes include robust revenue growth in energy (Vistra exceeding EBITDA guidance by $112M, Energy Vault +341% YoY to $203.7M) and select retail/biotech sectors, contrasted by widespread margin compression (e.g., Home Depot operating income -2.9% YoY, Bob's Discount gross margin -110 bps to 45.7%) and persistent net losses in 12+ companies despite top-line gains. Portfolio-level trends show 18/50 filings with YoY revenue acceleration (avg +45% in high-growers like Accelerant +51.5%), but 15 report widening losses or equity erosion (e.g., Natural Resource net loss +2-6% YoY, cash at $0); capital returns remain strong with $5.75B Vistra buybacks since 2021 and dividends in banks like Great Southern $0.43/share. Critical developments: Biotech catalysts (Arvinas Phase 1 success >50% LRRK2 degradation), M&A progress (Two Harbors-UWM), and dilution risks (Creative Media 261M shares issued). Market implications favor energy/utilities outperformance amid strategic PPAs/acquisitions, while retail faces transaction declines (Home Depot -2.2% customers YoY); blue-chip stability via credit extensions (Hilton) signals resilience, but watch governance shifts and exec transitions in 10+ firms for conviction gauges.

33 high priority 17 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — March 18, 2026

Across 50 SEC filings for March 18, 2026, overarching themes include mixed financial results in 10-Ks with revenue growth in standout performers like TSS Inc (+66% YoY to $245.7M) and Bob's Discount Furniture (+16.8% YoY to $2.37B), contrasted by declines in Harte Hanks (-13.9% YoY) and persistent losses in microcaps like NRHI (net loss +6% YoY to $30.6K, zero cash). M&A activity dominates with proxy supplements for Heritage Commerce/CVB Financial (shareholder meetings March 26) and Two Harbors/UWM due to litigation risks, while capital allocation shows buybacks (TSS 988 shares, XOMA $16M, News Corp $1B program) and dividends (Heartland quarterly). Period-over-period trends reveal improving net losses in Stardust Power (-34% YoY) and XOMA (to $31.7M profit from loss), but margin compression in Bob's (-110 bps to 45.7%) and expense surges in Vyome (+790% op ex). Sector patterns highlight banking M&A hurdles, AI/tech growth (TSS backlog $115M), and pharma pipeline advances amid auditor switches (Tonix to PwC). Forward catalysts cluster in Q2 2026 (XOMA volixibat data) with IPO/ETF launches (Farlong $16M, Morgan Stanley Bitcoin). Implications favor selective longs in growth outliers amid broad small-cap weakness and litigation overhangs.

28 high priority 22 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — March 18, 2026

Across 50 SEC filings from S&P 500 Consumer Discretionary and related streams, overarching themes include modest revenue growth in retail (e.g., Five Below +22.9% YoY, Bob's Discount +16.8% YoY, Home Depot +3.2% YoY) offset by widespread margin compression (e.g., Bob's gross margin -110 bps to 45.7%, Home Depot ROIC -570 bps to 25.7%) and mixed profitability trends, with 7/12 key financial reporters showing net income improvements averaging +45% YoY but operating losses in high-growth names like HeartFlow (-$117M). Capital allocation leans toward debt expansions (Hilton RCF extension, Hyperfine $40M facility) and M&A (RocketFuel asset sale, FingerMotion Telforge acquisition), signaling liquidity management amid volatility. Forward-looking guidance is optimistic in retail (Five Below FY26 sales $5.20-5.30B, comp +3-5%) but cautious on cash burn (Hyperfine $26-28M). Portfolio-level patterns reveal 6/10 retail filings with comp sales acceleration (avg +10% YoY) but inventory builds (Home Depot +10%, Bob's +15%) hinting demand risks. Neutral sentiment dominates (28/50 filings), with positive financing/M&A catalysts and proxy season ramp-up offering near-term volatility. Critical implications: Favor high-comp growth like Five Below over decelerating giants like Home Depot; monitor Q1 FY26 guidance for margin recovery.

30 high priority 20 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — March 18, 2026

Across the 33 filings in the USA S&P 500 Healthcare stream (with broader cross-sector context), healthcare firms show mixed performance: service providers like Pacific Health Care Organization achieved +11% YoY revenue and +57% net income growth, while device/biotech players like Lifeward (-14% FY revenue) and Cingulate (+35% net loss YoY) faced headwinds amid Nasdaq compliance risks (e.g., CalciMedica) and funding needs (Artelo Biosciences bridge notes). Financial peers (non-core but contextual) displayed resilient net income growth averaging +55% YoY (Sound Financial +54%, AmeriServ +56%) with NIM expansions (+45bps to +34bps), contrasting healthcare's revenue declines in 3/7 key firms averaging -14%. Proxy season ramps up with healthcare giants like Boston Scientific filing DEFA14A/DEF14A, signaling governance focus; capital allocation leans conservative (e.g., First Financial $0.56 dividend). Forward catalysts cluster in H1 2026, including Cingulate's PDUFA May 31 and CalciMedica compliance deadlines Sep 2026. Portfolio implication: favor healthcare services over devices/biotech amid volatility, monitor small-cap delisting risks.

18 high priority 15 medium 33 total filings
· daily

Global High-Priority Regulatory Events — March 18, 2026

Across 50 filings in the Global High Priority Market Events stream (US SEC focus, March 18, 2026), dominant themes include heightened regulatory scrutiny with 7+ Indian-listed firms facing SEBI/BSE/NSE fines for delayed financials (totaling ~₹30L+), active M&A/takeover landscape via open offers and mergers (e.g., Nilachal Refractories, Heritage Commerce), and mixed financial performances in 10-Ks showing revenue surges in winners like TSS Inc (+66% YoY to $245.7M) offset by widening losses (e.g., dMY Squared -2145% YoY net loss). Period-over-period trends reveal strong growth outliers (avg +40% YoY revenue in consumer/industrials like Bob's Discount +16.8%, Magnum Ice Cream +4.2% organic) but margin compression (Bob's -110 bps gross) and zero-cash shells (Natural Resource Holdings). Capital allocation leans conservative with minor buybacks (TSS 988 shares) and upcoming dividends (ICICI, TVS), while forward-looking catalysts cluster around April board meetings and March 26 shareholder votes. Portfolio-level patterns flag India regulatory risks, SPAC/merger momentum, and AI/consumer growth amid ABS servicing stability. Critical implications: Monitor M&A for takeover premiums, avoid fine-hit microcaps, chase growth outliers pre-earnings.

50 high priority 50 total filings
· daily

US IPO Pipeline SEC S-1 Filings — March 18, 2026

The single S-4 filing in the IPO Pipeline stream highlights a high-materiality (9/10) SPAC merger to form Pubco, a digital asset treasury company with primary XRP exposure, backed by over $1B in equity commitments at $10.00 per share and initial holdings of at least 473M XRP from Ripple and sponsors. Mixed sentiment stems from strong structural support like Up-C tax efficiency, six-month lockups on key shares, and a fairness opinion from CCM, offset by risks such as high SPAC redemptions potentially dropping cash below the $5M closing minimum and minority positioning for existing SPAC shareholders. No period-over-period financial trends are disclosed in the filing, but the transaction implies robust pre-merger capital inflows versus typical SPAC dilutions. Leadership by CEO Asheesh Birla and Ripple advisors signals conviction in XRP yield generation and ecosystem strategies. This positions Pubco as a rare public vehicle for concentrated XRP exposure amid crypto market volatility, with implications for IPO-like liquidity in digital assets. Portfolio-level theme: Resurgent SPAC activity targeting niche crypto treasuries despite redemption pressures.

1 high priority 1 total filings
· daily

US Earnings Financial Results SEC Filings — March 18, 2026

Across 50 10-K and 10-Q filings for FY2025 (mostly ended Dec 31, 2025, filed Mar 18, 2026), dominant mixed sentiment prevails in 70% of detailed reports, with revenue growth in 18/25 quantifiable companies averaging +72% YoY (skewed by outliers like Energy Vault +341%, ProKidney +1,075%, TSS +66%), but offset by widespread margin compression (e.g., 9/15 cases -100bps+), persistent net losses (12/25 widening or flat), and yield declines in investment vehicles (e.g., Unknown #1 9.9% from 11.2%, PGIM 9.88% from 11.11%). Retailers like Home Depot (+3.2% sales) and Best Buy (+0.4%) show resilience via comp sales stability but earnings pressure from costs/stores cuts; tech/AI firms (TSS, Energy Vault, ONE STOP) drive outsized growth amid capex; biotechs (Heartflow +40%, 4DMT +huge via licenses) narrow losses post-IPO/financing but burn cash. Capital allocation leans to financings/debt (e.g., Bob's $337M new LT debt, Accelerant $1.38B distributions causing loss swing), sparse buybacks (TSS minor repurchase); ABS servicing filers (12/50) uniformly neutral/low materiality with no deficiencies. Portfolio implication: Favor high-growth tech/biotech turnarounds over flat retail/banks amid yield headwinds; watch Q1'26 catalysts for guidance.

50 high priority 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — March 18, 2026

Across 41 DEF 14A proxy statements, a dominant theme is strong 2025 financial performance in energy/utilities (e.g., Vistra's $5.912B Adjusted EBITDA exceeding guidance by $112M, NRG's 167% AIP EBITDA attainment) and financials (Wells Fargo's $21.3B net income, 12.4% ROE), with portfolio-level YoY revenue/earnings growth in 12/15 metric-disclosing firms averaging +15%, though mixed in semis/oil services (Lattice GAAP NI -95% YoY). Capital returns shine with $1.6B+ repurchases/dividends in multiple (NRG $1.65B, California Resources $513M), signaling management conviction amid robust governance (no hedging/pledging common). Merger activity (Black Hills-NorthWestern, California Resources-Berry) and CEO transitions (NRG, Regal Rexnord) add catalysts, with 30+ virtual annual meetings in late April-May 2026 as key voting events for comp approvals (97% prior support at Vistra). Sentiment skews positive/neutral (28/41), but outliers like premium declines (Assured Guaranty GWP down YoY) flag sector pressures. Implications: Bullish for utilities/energy on returns/growth; monitor REITs/banks for comp votes influencing retention.

41 high priority 41 total filings
· daily

US Executive Officer Management Changes SEC — March 18, 2026

Across 33 SEC filings on US executive and director changes from March 18, 2026, the dominant theme is high turnover with 18 appointments (CFOs, COOs, directors) and 15 departures/retirements, signaling proactive board refreshes in consumer (Coty) and energy sectors but potential instability in biotech (Hepion CEO resignation) and tech (SoundHound CFO exit). Sentiment skews neutral (20/33) with positive tones in 9 cases driven by experienced hires (e.g., Seadrill's Samir Ali, Waste Connections' Daniel Florness), while mixed in growth stories like Accelerant (24% YoY Q4 premium growth to $1.09B but $1.345B FY loss). Period-over-period data sparse but highlights Accelerant's outlier EBITDA surge 149% FY to $282M amid CFO change; no broad margin compression but continuity awards (Eagle $1.175M cash) flag CEO transitions. Portfolio-level patterns show CFO churn in 7 firms (40% small/mid-caps), board expansions in infra/healthcare, and comp-heavy inducements (LifeMD 675K RSUs). Implications: bullish for stable transitions with growth guidance (Accelerant Q1 EBITDA $64-66M), bearish for sudden exits amid suspensions (Graphjet); investors should monitor Q1 earnings for post-change execution.

33 high priority 33 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — March 18, 2026

Across 31 filings in the USA Corporate Distress & Bankruptcy stream, a dominant theme is aggressive liquidity pursuits through debt facilities, equity issuances, note extensions, and credit amendments, with 18 companies (58%) announcing new/expanded financing amid potential distress signals like Nasdaq delisting notices in 2 cases and dilutive convertible notes in 5. Period-over-period data is sparse but highlights outliers: Ovid Therapeutics revenue surged 1117% YoY to $7.3M with opex down 20% to $49.7M and net loss halved to $17.4M, contrasting minimal quantitative trends elsewhere. Positive catalysts include M&A (e.g., Independent Bank's $70.2M accretive deal, ConnectM's defense acquisition) and buybacks (ExlService's $125M ASR), while risks cluster around equity dilution, reverse splits, and compliance deadlines into Q3-Q4 2026. Portfolio-level patterns show capital allocation skewed to debt preservation (e.g., Hilton, Socket Mobile extensions) over returns, with no insider buying/selling clusters but related-party deals in 4 filings signaling governance watchpoints. Forward-looking data builds a catalyst calendar heavy on approvals, closings, and trial readouts, implying short-term volatility in microcaps. Overall, distress signals are mixed with turnaround financing opportunities, but Nasdaq risks and high-interest notes flag 7 high-risk names warranting avoidance.

31 high priority 31 total filings
· daily

US SEC Trading Suspension Halt Orders — March 18, 2026

Both CalciMedica, Inc. (CALC) and Glimpse Group, Inc. (GGRP) received Nasdaq deficiency notices on March 13-16, 2026, primarily for failing the minimum bid price requirement (closing below $1.00/share for 30 consecutive business days), with CALC additionally cited for MVLS below $35M, stockholders' equity, and net income standards under Rules 5550(b)(1)/(3). No period-over-period financial trends are detailed in filings, but implied weak performance (low MVLS/equity/net income) signals deteriorating fundamentals amid small-cap pressures. Trading remains uninterrupted for both, providing 180 calendar days to regain compliance by September 9-14, 2026, via measures like reverse stock splits, though success is uncertain. Negative sentiment across filings (materiality 9/10) underscores heightened delisting risks, with no reported insider activity, capital allocation changes, or forward guidance to counter bearish outlook. Portfolio-level pattern: 2/2 companies in Nasdaq Capital Market face simultaneous compliance threats, highlighting microcap vulnerability in biotech (CALC) and emerging tech (GGRP) sectors. Implications include potential volatility from reverse splits or delistings, urging avoidance or short strategies.

2 high priority 2 total filings
· daily

US Corporate Board Director Changes SEC Filings — March 18, 2026

Across 33 US SEC filings on board room changes from March 18, 2026, the dominant theme is high executive turnover, particularly CFOs and controllers (10+ cases including New ERA, McCormick, LifeMD, Accelerant, SoundHound, Cyber Enviro-Tech, MPLX), with 60% involving appointments of experienced internals/externals signaling stability amid growth pushes. Positive sentiment prevails in 30% of filings (e.g., Seadrill CEO promotion, Coty board refresh, LifeMD triple hires), neutral in 60% (resignations without discord), and mixed in key growth firms like Accelerant (24% YoY Q4 revenue to $1.09B but $1.345B FY loss) and SoundHound (8x revenue growth under departing CFO). Period trends show strong growth outliers like Accelerant EBITDA +149% FY to $282M and third-party premiums to 40% mix (from 21%), but misses like Playstudios FY2025 PSUs forfeited. Forward-looking includes Accelerant Q1 2026 EBITDA $64-66M and FY $275M+, with equity incentives tied to targets (e.g., VisionWave $100M revenue milestone). Capital allocation leans to retention via RSUs/PSUs (e.g., Eagle Bancorp $1.175M cash + RSUs, Playstudios new PSUs post-forfeit). Portfolio-level: Healthcare/biotech sees CEO volatility (Hepion sudden resign), energy stable promotions; actionable now: Buy dips on positive hires, watch transitions for volatility.

33 high priority 33 total filings
· daily

US Merger & Acquisition SEC Filings — March 18, 2026

The 13 filings reveal robust M&A and SPAC activity centered on business combinations, extensions, and niche sector acquisitions, with 10/13 involving SPACs showing persistence amid challenges like high redemptions (Voyager: 25.2M shares redeemed, trust at $885k) and one termination (Quartzsea due to CSRC delays). Positive divestitures and acquisitions dominate non-SPAC activity: TriMas $1.45B Aerospace sale yields $1.2B for growth/buybacks; BlockchAIn completes combo with $22.9M rev/$5.7M NI data center targeting AI expansions 2026-27; cannabis M&A surges via Grown Rogue (60% cost savings, Q2 2026 ops) and Global Asset (license options). No period-over-period declines reported across filings (e.g., BlockchAIn 2024 metrics strong, TriMas no quantitative drops); forward looks cluster in Q2-Q4 2026 for operations/expansions. Portfolio trends: Neutral routine SPAC mechanics (unit separations in 2, extensions in 3) mask bullish niche growth in AI/HPC, cannabis, packaging; bearish regulatory hurdles in PRC-related deals. Implications: Capital recycling fuels buybacks/acquisitions; monitor SPAC closings for dilution risks, alpha in post-combo trading (e.g., AIB ticker).

13 high priority 13 total filings
· monthly

US Pre-Market SEC Filings Roundup — March 18, 2026

Across 50 overnight SEC filings, overarching themes include robust revenue growth in select consumer, tech services, and royalty firms (e.g., TSS +66% YoY, Bob's Discount +16.8% YoY, XOMA +83% YoY revenues) contrasting with persistent losses and margin pressures in small-caps and biotechs (e.g., NRHI net loss +2-6% YoY, Harte Hanks revenues -13.9% FY). M&A and proxy activity dominates with supplements for Heritage Commerce/CVB merger amid lawsuits, Two Harbors/UWM, and StableCoinX SPAC, signaling heightened litigation risks but on-track closings. Capital allocation trends favor buybacks (TSS, XOMA $16M, News Corp $1B program) and dividends (Heartland Express), while forward-looking catalysts cluster in Q2-H2 2026 (XOMA trials, Magnum 3-5% organic growth targets). Portfolio-level patterns show 7/12 detailed 10-Ks with mixed sentiment, averaging +20% revenue growth but frequent net loss widening due to op ex surges (Vyome +790% YoY). Sector outliers include strong consumer recovery (Bob's comp sales +7.7%) and ETF launches (Morgan Stanley Bitcoin Trust). Market implications point to alpha in growth outperformers and merger arb, with caution on dilution/control risks (Cyber Enviro-Tech, Laser Photonics).

28 high priority 22 medium 50 total filings
· daily

Biotech Small-Cap Approvals — March 17, 2026

FDA approved four standard ANDA generics on March 10-11, 2026—CEVIMELINE HYDROCHLORIDE (Zydus Lifesciences), BRIMONIDINE TARTRATE (Gland), LIRAGLUTIDE (Biocon Pharma), and METFORMIN HYDROCHLORIDE/SITAGLIPTIN (Apotex Inc)—all original approvals with no special designations or priority review. This 100% neutral cluster signals routine pipeline execution for generics sponsors but no novel innovation or high-impact catalysts. Two diabetes-related approvals (Liraglutide, Sitagliptin combo) highlight modest erosion potential in that segment amid pricing risks.

4 total filings
· daily

New Drug Approvals (Original) — March 17, 2026

Four ANDA generic approvals on March 10-11, 2026, for Zydus Lifesciences, Gland, Biocon Pharma, and Apotex Inc., all under standard review with no special designations, signal routine portfolio expansions for generics sponsors. Neutral implications dominate due to lack of novel features, therapeutic details, or premium positioning, with two approvals in diabetes-related drugs (Liraglutide, Metformin/Sitagliptin combo). Cluster indicates FDA batch processing efficiency but heightens generic competition risks without quantified market impacts.

4 total filings